UNLABELLED: Atherosclerosis is the pathophysiologic process behind lethal cardiovascular diseases. It is a chronic inflammatory progression. Chemokines can strongly affect the initiation and progression of atherosclerosis by controlling the trafficking of inflammatory cells in vivo through interaction with their receptors. Some chemokine receptors have been reported to play an important role in plaque development and stability. However, the diagnostic potential of chemokine receptors has not yet been explored. The purpose of this study was to develop a positron emitter-radiolabeled probe to image the upregulation of chemokine receptor in a wire-injury-accelerated apolipoprotein E knockout (ApoE(-/-)) mouse model of atherosclerosis. METHODS: A viral macrophage inflammatory protein II (vMIP-II) was used to image the upregulation of multiple chemokine receptors through conjugation with DOTA for (64)Cu radiolabeling and PET. Imaging studies were performed at 2 and 4 wk after injury in both wire-injured ApoE(-/-) and wild-type C57BL/6 mice. Competitive PET blocking studies with nonradiolabeled vMIP-II were performed to confirm the imaging specificity. Specific PET blocking with individual chemokine receptor antagonists was also performed to verify the upregulation of a particular chemokine receptor. In contrast, (18)F-FDG PET imaging was performed in both models to evaluate tracer uptake. Immunohistochemistry on the injury and sham tissues was performed to assess the upregulation of chemokine receptors. RESULTS: (15)O-CO PET showed decreased blood volume in the femoral artery after the injury. (64)Cu-DOTA-vMIP-II exhibited fast in vivo pharmacokinetics with major renal clearance. PET images showed specific accumulation around the injury site, with consistent expression during the study period. Quantitative analysis of tracer uptake at the injury lesion in the ApoE(-/-) model showed a 3-fold increase over the sham-operated site and the sites in the injured wild-type mouse. (18)F-FDG PET showed significantly less tracer accumulation than (64)Cu-DOTA-vMIP-II, with no difference observed between injury and sham sites. PET blocking studies identified chemokine receptor-mediated (64)Cu-DOTA-vMIP-II uptake and verified the presence of 8 chemokine receptors, and this finding was confirmed by immunohistochemistry. CONCLUSION: (64)Cu-DOTA-vMIP-II was proven a sensitive and useful PET imaging probe for the detection of 8 up-regulated chemokine receptors in a model of injury-accelerated atherosclerosis.
UNLABELLED: Atherosclerosis is the pathophysiologic process behind lethal cardiovascular diseases. It is a chronic inflammatory progression. Chemokines can strongly affect the initiation and progression of atherosclerosis by controlling the trafficking of inflammatory cells in vivo through interaction with their receptors. Some chemokine receptors have been reported to play an important role in plaque development and stability. However, the diagnostic potential of chemokine receptors has not yet been explored. The purpose of this study was to develop a positron emitter-radiolabeled probe to image the upregulation of chemokine receptor in a wire-injury-accelerated apolipoprotein E knockout (ApoE(-/-)) mouse model of atherosclerosis. METHODS: A viral macrophage inflammatory protein II (vMIP-II) was used to image the upregulation of multiple chemokine receptors through conjugation with DOTA for (64)Cu radiolabeling and PET. Imaging studies were performed at 2 and 4 wk after injury in both wire-injured ApoE(-/-) and wild-type C57BL/6 mice. Competitive PET blocking studies with nonradiolabeled vMIP-II were performed to confirm the imaging specificity. Specific PET blocking with individual chemokine receptor antagonists was also performed to verify the upregulation of a particular chemokine receptor. In contrast, (18)F-FDG PET imaging was performed in both models to evaluate tracer uptake. Immunohistochemistry on the injury and sham tissues was performed to assess the upregulation of chemokine receptors. RESULTS: (15)O-COPET showed decreased blood volume in the femoral artery after the injury. (64)Cu-DOTA-vMIP-II exhibited fast in vivo pharmacokinetics with major renal clearance. PET images showed specific accumulation around the injury site, with consistent expression during the study period. Quantitative analysis of tracer uptake at the injury lesion in the ApoE(-/-) model showed a 3-fold increase over the sham-operated site and the sites in the injured wild-type mouse. (18)F-FDG PET showed significantly less tracer accumulation than (64)Cu-DOTA-vMIP-II, with no difference observed between injury and sham sites. PET blocking studies identified chemokine receptor-mediated (64)Cu-DOTA-vMIP-II uptake and verified the presence of 8 chemokine receptors, and this finding was confirmed by immunohistochemistry. CONCLUSION: (64)Cu-DOTA-vMIP-II was proven a sensitive and useful PET imaging probe for the detection of 8 up-regulated chemokine receptors in a model of injury-accelerated atherosclerosis.
Authors: T N Kledal; M M Rosenkilde; F Coulin; G Simmons; A H Johnsen; S Alouani; C A Power; H R Lüttichau; J Gerstoft; P R Clapham; I Clark-Lewis; T N Wells; T W Schwartz Journal: Science Date: 1997-09-12 Impact factor: 47.728
Authors: D W McCarthy; R E Shefer; R E Klinkowstein; L A Bass; W H Margeneau; C S Cutler; C J Anderson; M J Welch Journal: Nucl Med Biol Date: 1997-01 Impact factor: 2.408
Authors: Y Liu; W Li; H P Luehmann; Y Zhao; L Detering; D H Sultan; H-M Hsiao; A S Krupnick; A E Gelman; C Combadiere; R J Gropler; S L Brody; D Kreisel Journal: Am J Transplant Date: 2016-07-14 Impact factor: 8.086
Authors: Jesse W Williams; Andrew Elvington; Stoyan Ivanov; Skyler Kessler; Hannah Luehmann; Osamu Baba; Brian T Saunders; Ki-Wook Kim; Michael W Johnson; Clarissa S Craft; Jae-Hoon Choi; Mary G Sorci-Thomas; Bernd H Zinselmeyer; Jonathan R Brestoff; Yongjian Liu; Gwendalyn J Randolph Journal: Circ Res Date: 2017-07-10 Impact factor: 17.367
Authors: Soraya M Kazuma; Deborah Sultan; Yongfeng Zhao; Lisa Detering; Meng You; Hannah P Luehmann; Dulcineia S P Abdalla; Yongjian Liu Journal: Curr Pharm Des Date: 2015 Impact factor: 3.116
Authors: Hannah P Luehmann; Lisa Detering; Brett P Fors; Eric D Pressly; Pamela K Woodard; Gwendalyn J Randolph; Robert J Gropler; Craig J Hawker; Yongjian Liu Journal: J Nucl Med Date: 2016-01-21 Impact factor: 10.057
Authors: Hannah P Luehmann; Eric D Pressly; Lisa Detering; Cynthia Wang; Richard Pierce; Pamela K Woodard; Robert J Gropler; Craig J Hawker; Yongjian Liu Journal: J Nucl Med Date: 2014-03-03 Impact factor: 10.057
Authors: Pamela K Woodard; Yongjian Liu; Eric D Pressly; Hannah P Luehmann; Lisa Detering; Deborah E Sultan; Richard Laforest; Alaina J McGrath; Robert J Gropler; Craig J Hawker Journal: Pharm Res Date: 2016-06-10 Impact factor: 4.200